Actively Recruiting
IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
Led by Sun Yat-sen University · Updated on 2026-04-13
2000
Participants Needed
1
Research Sites
8 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to explore the relationship between blood and urine biomarkers, including genetic variants, and the long-term progression of kidney disease in Chinese patients with IgA nephropathy who have relatively normal kidney function. IgA nephropathy is a common cause of kidney disease leading to end-stage renal disease in China, with highly variable outcomes among individuals. The study seeks to integrate genetic and biomarker information to better predict disease progression. The study is observational and involves 2000 patients diagnosed with primary IgA nephropathy confirmed by biopsy. There is no intervention or treatment administered as part of this trial. Participants have had their first kidney biopsy within the last 3 years and maintain an estimated glomerular filtration rate (eGFR) of 60 ml/min/1.73 m2 or higher. Participants will be followed over a period of up to 120 months to monitor kidney function changes and disease progression. Researchers will measure key outcomes such as doubling of serum creatinine, progression to end-stage renal disease requiring dialysis or transplantation, and death. Secondary outcomes include remission of proteinuria. Data collection involves reviewing biopsy samples and monitoring clinical markers over time to understand disease trajectories.
CONDITIONS
Brief Title
IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female individuals aged 14 years or older
- Patients with biopsy-proven primary IgA nephropathy
- Renal biopsy available for review must include 10 or more glomeruli
- First renal biopsy performed within the past 3 years
- Estimated glomerular filtration rate (eGFR) of 60 ml/min/1.73 m2 or higher
- Ability to understand and voluntarily sign informed consent
You will not qualify if you...
- Relatives diagnosed with biopsy-proven primary IgA nephropathy
- Secondary IgA nephropathy caused by diseases like diabetes, chronic liver disease, or systemic lupus erythematosus
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 120 months
Participants with biopsy-proven primary IgA nephropathy are observed over time to evaluate kidney disease progression and biomarker associations.
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital,Sun Yat-sen University
Guangzhou, Guangdong, China, 510080
Actively Recruiting
Research Team
X
Xue Qing Yu, M.D. & Ph.D.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here